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with eosinophilic chronic rhinosinusitis with nasal polyps
Chengshuo Wang, MD,a,b* Hongfei Lou, MD,a,b* Xiangdong Wang, MD,a,b Yang Wang, BS,b Erzhong Fan, BS,b
Ying Li, BS,b Hong Wang, BS,b Claus Bachert, MD,c and Luo Zhang, MDa,b Beijing, China, and Ghent, BelgiumBackground: There is little evidence on the efficacy of
glucocorticoid transnasal nebulization therapy in patients
with eosinophilic chronic rhinosinusitis with nasal polyps
(CRSwNP).
Objective: We sought to evaluate the immunologic and
remodeling effects of budesonide transnasal nebulization in
patients with eosinophilic CRSwNP.
Methods: Sixty patients with eosinophilic CRSwNP were
randomized to receive budesonide or placebo treatment for
14 days by means of transnasal nebulization in a double-blind
manner. Endoscopic polyp size scores (maximum 5 6 points,
Kennedy score) and visual analog scale scores for nasal
symptoms were assessed before and after treatment. Similarly,
polyp samples were evaluated for inflammatory cytokines,
matrix metalloproteinases (MMPs), and tissue inhibitors of
metalloproteinases (TIMPs) by using an immunoassay;
collagen by using histochemistry; eosinophils by using
hematoxylin and eosin stain; and T-cell subsets by using flow
cytometry.
Results: Budesonide transnasal nebulization significantly
reduced polyp size compared with placebo (mean difference
between groups, 20.73 units; 95% CI, 21.15 to 20.32 units;
P 5 .002) and improved symptoms. Polyp IL-5 and eotaxin
expression decreased significantly, whereas TGF-b and IL-10
expression increased. Expression of IFN-g and IL-17 was not
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922reduced eosinophil infiltration and TH2 cell frequency and
increased natural regulatory T-cell and type 1 regulatory
T-cell frequencies. Indices of remodeling, including albumin,
MMP-2, MMP-7, MMP-8, and MMP-9, were significantly
decreased, whereas collagen deposition and TIMP-1, TIMP-2,
and TIMP-4 levels were significantly increased. Budesonide
transnasal nebulization did not suppress the hypothalamic-
pituitary-adrenal axis or cause any serious side effects.
Conclusion: Short-term budesonide transnasal nebulization is
an effective and safe treatment option in patients with
eosinophilic CRSwNP, achieving clinical improvement by
regulating remodeling, cytokine expression, and T-cell subset
distribution. (J Allergy Clin Immunol 2015;135:922-9.)
Key words: Eosinophilic chronic rhinosinusitis, nasal polyps, tissue
remodeling, inflammatory cytokine, T-cell subsets, budesonide,
transnasal nebulization
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a major
health care problem that affects from 0.5% to 4% of the general
population.1 CRSwNP leads to high management costs and poor
quality of life of affected subjects and shows a wide diversity of
inflammatory phenotypes. Studies have demonstrated that
eosinophil infiltration and TH2-biased cytokine profiles are key
features of white patients with CRSwNP,2,3 whereas nasal polyps
(NPs) from southern Chinese patients have been shown to be
characterized by neutrophilic inflammation and a significant
increase in TH1/TH17 cell pattern.
4
Given the inflammatory nature of CRSwNP, corticosteroids are
typically regarded as the mainstay of medical treatment for
this condition.1 Although topical intranasal steroid sprays
have proved to be an effective treatment for chronic
rhinosinusitis (CRS) and maintain a minimal risk profile,5
long-term administration of nasal spray is necessary to obtain a
persistent therapeutic effect. Furthermore, despite providing
more potent and rapid benefits in controlling inflammation
associated with CRS,6,7 systemic corticosteroids have significant
side effects, such as hypothalamic-pituitary-adrenal axis dys-
function. Thus a need has arisen for an alternative topical therapy
in patients with CRS.
Budesonide inhalation suspension (Pulmicort Respules;
AstraZeneca, London, United Kingdom) is another form of
corticosteroid therapy, which has been demonstrated to be
efficacious and safe in patients with asthma8 or chronic obstruc-
tive pulmonary disease.9 However, there is little information on
the use of budesonide transnasal nebulization in the treatment
of inflammatory nasal disease.
Thus the aim of this study was first to evaluate the clinical
efficacy and safety of a short-term course of budesonide inhalation
suspension delivered by means of transnasal nebulization in
patients with CRSwNP. In addition, the study aimed to investigate
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nasal tissue remodeling (namely differences in the expression of
collagen, albumin, TGF-b, matrix metalloproteinases [MMPs],
and tissue inhibitors of metalloproteinases [TIMPs]) in these
patients.METHODS
Patients and study design
Sixty patients with eosinophilic NPs were recruited into this prospective,
randomized, double-blind, placebo-controlled study (clinical trial registration
details available from http://clinicaltrial.gov/show/NCT02024659) from
Beijing TongRenHospital, Beijing, China, fromSeptember 2010 toDecember
2011. At the screening visit, participants were preselected for eosinophilic
NPs based on at least 1 of the following parameters: skin prick test response
positivity, increased eosinophil counts in peripheral blood, allergic rhinitis,
asthma, or aspirin intolerance. The diagnosis of CRSwNP was based on the
standard criteria issued in the European Position Paper on Rhinosinusitis
and Nasal Polyps guidelines.10 Polyp biopsy was undertaken 1 week before
treatment. Referring to the method of Cao et al,11 CRSwNP was defined as
eosinophilic when the number of eosinophils exceeded 10% of total
infiltrating inflammatory cells in the polyp tissue, as evaluated by using
hematoxylin and eosin (H&E) staining.
Eligible patients were randomly assigned 1:1 to receive 1mg of budesonide
or placebo (saline solution) transnasal nebulization twice daily for 14 dayswith
a Pari Sinus Nebulizer and Pari Master Compressor (PARI GmbH, Starnberg,
Germany). The studymedicationwas delivered in a double-blindmanner, with
neither the patient nor the investigator knowing the identity of the medication.
Nasal symptoms (including nasal obstruction, nasal discharge, loss of smell,
and headache/facial pain) were assessed before initiation (1 week after biopsy)
and at the end of the 14-day treatment period by using visual analog scales. The
total nasal symptom score (TNSS) was calculated as the sum of scores for 4
individual symptoms at the same time. Similarly, the size of NPswasmeasured
by means of endoscopic examination at baseline and the end of the study with
the Kennedy score (full details are available in this article’s Online Repository
atwww.jacionline.org). Polyp sizewas scored from0 to 3 for each side, and the
bilateral polyp gradewas obtained as the sum of the individual units for the left
and right nasal cavities (maximum score5 6). The physician’s assessment of
reduction in NP size and the patient’s assessment of improvements in
symptoms were used as clinical end points.
Biopsy specimens of NPs were obtained again after the 14-day treatment
period for assessment of the effect of treatment on several markers of
inflammation and nasal tissue remodeling (namely expression of collagen,
albumin, TGF-b, MMPs, and TIMPs) as secondary outcome measures. All
patients were also assessed before and after treatment for morning serum
cortisol levels, and adverse events were reported to the investigator, who
assessed the relationship of the event to the study treatment.
Full technical details of the methods used in this randomized, double-blind
study design and efficacy end points are provided in the Methods section in
this article’s Online Repository.The study was approved by the medical ethics committee of Beijing
TongRen Hospital, and written informed consent was obtained from each
patient before participation in the study.Histologic examination
Human NP tissue was assessed by means of H&E staining to determine
eosinophil infiltration. Samples from patients in both groups were evaluated in
a blind fashion with respect to the pretreatment and posttreatment sequences.
Full technical details are provided in the Methods section in this article’s
Online Repository.Immunoassay
Levels of inflammatory cytokines (including IL-5, IFN-g, IL-17, IL-10,
TGF-b, and eotaxin),MMPs (MMP-2,MMP-7,MMP-8, andMMP-9), TIMPs
(TIMP-1, TIMP-2, TIMP-3, and TIMP-4), and albumin in tissue homogenates
were evaluated by means of immunoassay. Full technical details are provided
in the Methods section in this article’s Online Repository.Picrosirius red staining for collagen
The collagen content in the extracellular matrix was assessed by means of
picrosirius red staining. Full technical details are provided in the Methods
section in this article’s Online Repository.Flow cytometric analysis
TH1, TH2, TH17, type 1 regulatory T (TR1) cells (the most important subset
of inducible regulatory T [Treg] cells, which secrete IL-10 and TGF-b), and
natural regulatory T (nTreg) cells, which are thymus derived and characterized
by their CD41CD251 forkhead box protein 3 (Foxp3)–positive phenotype, in
polyp homogenates were evaluated by means of cytometric analysis. Full
technical details are provided in the Methods section in this article’s Online
Repository. Representative gating figures are also shown in Fig E1 in this
article’s Online Repository at www.jacionline.org.Safety assessment
Safetywas assessed primarily based on changes in plasma cortisol levels by
the end of treatment. Venous blood samples were obtained at 8 AM on the first
and last days of treatment and analyzed for plasma cortisol by means of RIA.
The secondary safety variablewas the incidence and severity of adverse events.Statistical analysis
The sample sizewas estimated based on power statistics by using reduction
in NP size as the primary outcome measure. On the basis of our preliminary
findings of a pilot study, we estimated that by using a parallel-group design, 18
subjects per group would be required to detect a 0.8-unit difference in polyp
size reduction between randomized treatments at 2 weeks (combined SD, 0.7)
with a power equal to 90% and a 2-tailed a value of .05. Considering a loss of
10% of patients at follow-up for the clinical portion of the study and a dropout
rate of 50% for biopsies, we recruited 30 participants in each study group.
Statistical analysis was performed with SPSS version 19.0 software (IBM,
Armonk, NY). Data were expressed as means and SEMs, unless otherwise
specified. Continuous variable differences were analyzed by using the Student
t test or Mann-Whitney U test for unpaired comparisons. A P value of .05 or
less was considered statistically significant.RESULTS
Patients’ clinical characteristics
Overall, 93 patients were screened for eligibility, of whom
60 met the inclusion criteria and were randomized in equal
numbers to receive budesonide or placebo nebulization therapy
FIG 1. Study patients’ flow diagram.
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the placebo group dropped out because of nonadherence (Fig 1).
The 2 groups were well matched in demographic characteristics,
symptom severity (TNSS), polyp size, and concurrent illness at
baseline. Relevant data are presented in Table E1 in this article’s
Online Repository at www.jacionline.org.Clinical responses as primary outcomes
By the end of the 14-day treatment period, assessment of
the NP size demonstrated that it was significantly decreased in
budesonide-treated patients compared with that seen in
placebo-treated patients (mean difference between groups,
20.73 units; 95% CI, 21.15 to 20.32 units; P 5 .002; Fig 2,
A). Patients receiving budesonide transnasal nebulization also
showed significant improvements in the 4 major symptoms
compared with patients in the placebo-treated group (P < .001;
Fig 2, B-E). Similarly, assessment of TNSSs also indicated
that scores were significantly improved at the end of treatment
in the budesonide-treated patients compared with the placebo-
treated patients (P < .001; Fig 2, F).Inflammatory cytokines, mediators, and cellular
infiltration as secondary outcomes
Datawere not available for all subjects because of the relatively
small sizes of individual samples obtained. Thus all polyp tissues
were evaluated bymeans of H&E staining, and then samples from
patients in each treatment group were randomly divided into
approximately 3 equal groups. The 3 groups of samples were then
assessed for inflammatory cytokines, remodeling markers, or
T-cell subsets. For the inflammatory cytokines measured by using
the Cytometric Bead Array (BD Biosciences, San Jose, Calif),
which uses particles with discrete fluorescence intensities to
measure the concentration of specific analytes, there were 10
samples each in the active and placebo groups, and for TGF-b
levels measured by means of ELISA, there were 14 samples in the
active group and 12 samples in the placebo group. Moreover, the
concentration of IL-17 in samples from 4 subjects (2 each from
the budesonide- and placebo-treated groups) was less than the
limit of detection, and thus the value of the lower limit of
detection was assigned to these samples. Budesonide transnasal
nebulization significantly reduced eotaxin (Fig 3,A) and IL-5 (Fig
3, B) levels and significantly increased IL-10 (Fig 3, C) and TGF-b (Fig 3, D) levels in NPs compared with control values. In
contrast, IL-17 (Fig 3, E) and IFN-g (Fig 3, F) levels were not
significantly altered by budesonide transnasal nebulization.
Similarly, placebo treatment did not alter the level of any of these
cytokines compared with baseline values.
In linewith the observed cytokine patterns, eosinophil numbers
in NPs were significantly reduced after nebulized budesonide
treatment (Fig 4, A, and see Fig E2 in this article’s Online
Repository at www.jacionline.org) but not altered after placebo
treatment. Similarly, the frequency of TH2 cells in NPs was
significantly decreased by budesonide treatment (Fig 4, B),
whereas the frequencies of TH1 (Fig 4, C) and TH17 (Fig 4, D)
cells were not altered. Interestingly, budesonide transnasal
nebulization also significantly increased TR1 (Fig 4, E) and nTreg
(Fig 4, F) cell numbers. Placebo treatment did not significantly
alter the frequency of either of these cell types. Moreover, there
was a significant correlation between the change in TGF-b levels
and the change in nTreg cell numbers from baseline in the
nebulized budesonide–treated group (r2 5 0.56, P 5 .02, see
Fig E3 in this article’s Online Repository at www.jacionline.org).Tissue remodeling as a secondary outcome
Assessment of collagen deposition in the extracellular matrix
of NP tissues demonstrated that the total collagen amount
increased after a 14-day treatment with budesonide transnasal
nebulization (Fig 5,B, and Fig 6,A) butwas not altered by placebo
treatment. Whereas collagen type 1 was the most abundant
collagen type both before and after treatment, collagen type 3
(thinner fibers indicated by green luminescence) was almost
absent at baseline (Fig 5, C) and upregulated as new fibers were
produced after budesonide transnasal nebulization (Fig 5, D). In
contrast, albumin levels in NPs were significantly reduced by
budesonide transnasal nebulization but were unaltered after
placebo treatment (Fig 6, B). Similarly, expression of MMP-2
(Fig 6, C), MMP-7 (Fig 6, D), MMP-8 (Fig 6, E), and MMP-9
(Fig 6, F) was decreased after budesonide treatment compared
with that after placebo treatment. Assessment of TIMPs also
demonstrated that TIMP-1 (Fig 6, G), TIMP-2 (Fig 6, H), and
TIMP-4 (Fig 6, I) concentrations were significantly increased in
the budesonide-treated group and not affected by placebo
treatment. In contrast, the expression of TIMP-3 in the 2 treatment
groups showed no difference (data not shown).Safety
Plasma cortisol levels varied in the normal range in all
participants at baseline. Morning plasma cortisol levels showed
no significant difference between the initial treatment and the end
of treatment in both groups (18.076 1.98 vs 17.416 2.20 mg/dL
in the budesonide transnasal nebulization group and 17.336 1.83
vs 17.02 6 1.80 mg/dL in the placebo group, respectively). No
symptom of adrenal suppression was noted in any of the
participants, and no serious adverse events were reported during
the study, apart from nasal dryness in 5 patients in the budesonide
transnasal nebulization group.DISCUSSION
Anti-inflammatory agents, such as corticosteroids, are often
recommended as the drugs of choice by current CRS guidelines
FIG 2. Clinical improvements in the budesonide transnasal nebulization–treated group compared with the
placebo transnasal nebulization–treated group. Reductions in NP size and symptom improvements were
used as primary end points. A, NP size. B, Nasal congestion. C, Rhinorhea. D, Loss of smell. E, Headache. F,
TNSS. VAS, Visual analog scale.
FIG 3. Inflammatory cytokines and mediators in tissue homogenates were determined by using the
cytometric bead array (eotaxin, IL-5, IL-10, IL-17, and IFN-g) and ELISA (TGF-b).A, Eotaxin. B, IL-5. C, IL-10.D,
TGF-b. E, IL-17. F, IFN-g. NS, Not significant.
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FIG 4. Inflammatory cells in NP tissue were analyzed before and after treatment by using H&E staining
(eosinophils) and flow cytometric analysis (T-cell subsets). A, Eosinophils. B, TH2 cells. C, TH1 cells. D, TH17
cells. E, TR1 cells. F, nTreg cells. HPF, High-power field; NS, not significant.
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used as topical nasal medications administered as nasal drops12 or
delivered as aqueous sprays5 for sinonasal inflammatory diseases.
More recently, a new option for topical corticosteroid treatment in
patients with CRS has been the off-label use of budesonide
inhalation suspension in nasal lavage or irrigation.13-16 We have
investigated the efficacy and safety, as well as the putative
immunologic and tissue-remodeling mechanisms, underlying
the effects of short-term budesonide transnasal nebulization
treatment in patients with eosinophilic CRSwNP. Overall, our
study indicated that budesonide transnasal nebulization led to
significant improvements in all the major nasal symptoms and
reduced the size of NPs (primary outcome measures) in patients
with CRSwNP compared with placebo treatment. Moreover,
there were significant improvements in a variety of markers of
inflammation and tissue remodeling (secondary outcome
measures) in patients treated with budesonide transnasal
nebulization compared with placebo-treated patients.
The efficacy and safety of the budesonide inhalation
suspension as a means to perform nasal irrigation13 or lavage14
in patients with CRS without NPs or CRSwNP has been
investigated previously. A pilot study has demonstrated that the
addition of budesonide inhalation suspension (0.5 mg twice a
day) to nasal saline irrigation produced significant improvements
in subjective sinus symptoms and objective evaluation.13 Other
studies have demonstrated that budesonide inhalation suspension
neither suppressed the hypothalamic-pituitary-adrenal axis14,15
nor decreased serum and 24-hour urinary cortisol levels,16
suggesting that irrigation with budesonide was safe to perform
in patients with CRS as an alternative to traditional aerosolizedsteroid sprays or systemic corticosteroids. Our findings for the
clinical efficacy and safety of budesonide transnasal nebulization
in patients with CRSwNP are in accordance with the findings of
these studies. However, because the dose of budesonide used in
the study was twice as high as what has been advocated for
maintenance treatment,17 the possibility of systemic steroid-
related side effects if used longer than 14 days cannot be ruled
out. Long-term dose-dependent studies with nebulized
budesonide will be needed to fully appreciate the benefits of
this treatment modality for chronic management of inflammatory
nasal disease.
Nevertheless, using a similar NP grading score as used in the
present study, budesonide nasal spray18 has been shown to
produce similar reductions in polyp size after 4 weeks of
treatment, whereas mometasone furoate nasal spray5 achieved
similar improvements after 2 months of treatment. Collectively,
these results suggest that application of budesonide transnasal
nebulization might confer a faster onset of action, although this
would need to be confirmed in further studies comparing doses
similar to those used in nasal sprays.
In the present study we have also explored the immunologic
mechanisms underlying the beneficial clinical effects of
budesonide transnasal nebulization in patients with eosinophilic
CRSwNP. The attenuated production of eotaxin in our study
provided evidence of less eosinophil accumulation in NPs.
Furthermore, the anti-inflammatory potential of budesonide
inhalation suspension in this study was strengthened by the
observation that there was a significant reduction in TH2 cell
numbers in the local tissue. This finding is in accordance with
the findings of Van Zele et al,19 which demonstrated that oral
FIG 5. Picrosirius red–stained sections of polyp tissues from the same patient before and after budesonide
transnasal nebulization were assessed for total collagen by using bright-field microscopy (A and B) and for
collagen fibers by using polarized light microscopy (C and D) at 3200 magnification.
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significantly reduced eosinophil cationic protein, IL-5, and IgE
levels in nasal secretions in these patients. However, our study
has demonstrated that nebulized budesonide therapy was not
equally effective in inhibiting TH1/TH17-biased inflammation as
TH2-polarized inflammation. Our findings are in accordance
with previous studies that suggested TH1/TH17 cell infiltration
correlates with reduced sensitivity to corticosteroid therapy.20
The aforementioned data suggest a redirection of the cytokine
balance in vivo, which results in reversal of exaggerated TH2
cytokine expression after corticosteroid therapy. We speculated
that Treg cells might play a critical role in this rebalance and
therefore assessed nTreg and TR1 cells in NP tissue. Our result
of an increase in nTreg cell numbers after budesonide transnasal
nebulization was also consistent with findings of other authors for
intranasal mometasone.21 The finding of a significant correlation
between the change in TGF-b levels and the change in Treg cell
numbers in the present study suggests that TGF-b upregulation in
NP tissue promoted the induction of Treg cells.22 Additionally,
our finding for significant upregulation of TR1 cells and
associated suppressor cytokine IL-10 and TGF-b levels in NPs
from budesonide-treated patients support the notion that TR1 cells
are likely to play an anti-inflammatory role or roles in the
pathogenesis of CRSwNP.
TGF-b might be thought of as a double-edged sword, not only
inhibiting T-cell activation23 but also initiating structural
remodeling.22 Studies by Mastruzzo et al23 have demonstrated
that an increase in TGF-b1 cell numbers in NPs after corticoste-
roid treatment was accompanied by significant decreases in IL-41
and IL-51 cell numbers, as well as significant inhibition of
ongoing inflammatory responses. Additionally, other studies
have suggested that TGF-b was likely to play a critical role in
airway remodeling through induction of different profibroticprocesses and attraction of fibroblasts.22 Our findings for
excessive collagen production and thickening of collagen fibers,
coinciding with a significantly increased concentration of
TGF-b in the patients treated with budesonide transnasal
nebulization, are in accordance with these studies and suggest
that increased TGF-b expression and collagen deposition might
reflect an enhancement of tissue repair process. On the other
hand, it is possible that the increased collagen deposition noted
in this study might reflect a decrease in tissue edema to some
extent. Whether chronic use of budesonide is associated with
fibrosis in NPs remains unclear24 and needs to be explored further.
The balance between MMPs and TIMPs is important for
homeostasis of collagen synthesis and breakdown, and lower
expression of MMPs and higher amount of TIMPs were likely to
be regulated by increased TGF-b expression.25 Several studies
have shown that after corticosteroid treatment in patients with
asthma and nasal polyposis, there was a significant decrease of
MMP-2 and MMP-9 levels, respectively, combined with an
increase in TIMP-1 levels.26,27 Moreover, one study suggested
that tissueMMP-2/TIMP-1 andMMP-9/TIMP-1 ratios correlated
with the severity of NPs.26 The findings from the present study are
in accordance with these previous studies. It is possible that
budesonide treatment downregulated the expression of MMPs
at their main cell source level, including fibroblasts, eosinophils,
and mast cells,28 although this needs to be confirmed in future
studies.
Our study showed that albumin content in NPs was also
significantly reduced in the budesonide-treated group compared
with the placebo-treated group. Thus is consistent with the
findings of Bachert et al,3 who demonstrated that oral glucocorti-
coids significantly reduced albumin levels compared with no
treatment with glucocorticoids, which might lead to shrinkage
of NPs, an effect observed in our study.
FIG 6. Remodeling pattern shifts of NP tissues were evaluated in the budesonide transnasal nebulization–
and placebo transnasal nebulization–treated groups. A, Collagen. B, Albumin. C, MMP-2. D, MMP-7. E,
MMP-8. F, MMP-9. G, TIMP-1. H, TIMP-2. I, TIMP-4.
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significance levels for multiple comparisons. Although the prob-
abilities of type I error were low in primary outcomes, false-
positive results can occur in some secondary outcomes, including
IL-5,MMP-2,MMP-7,MMP-8, andMMP-9, as a result of the lack
of adjustment of the significance level. Thus the findings for these
secondary outcomes need to be interpreted with caution and
confirmed in further studies with larger patient cohorts.
Consistent with a previous report,29 the current study also
demonstrated budesonide transnasal nebulization therapy to be
safe and well tolerated, as evidenced by a lack of suppressive
effects on adrenal function (ie, normal posttreatment serum
cortisol levels) and the absence of serious side effects.
In conclusion, the results of this study indicate that short-term
budesonide inhalation suspension through a pulsating atomiza-
tion device (ie, budesonide transnasal nebulization) is an effectiveand safe treatment in patients with eosinophilic CRSwNP, as
evidenced by significant improvements in symptom scores and
inflammatory indices, reductions in polyp size, and the absence of
hypothalamic-pituitary-adrenal axis suppression or any serious
side effects.
Clinical implications: Short-term budesonide transnasal nebu-
lization significantly improves nasal symptoms, inflammation,
and tissue remodeling in the absence of any serious side effects
and thus offers an alternative treatment option for patients with
eosinophilic CRSwNP.REFERENCES
1. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012:
European position paper on rhinosinusitis and nasal polyps 2012. A summary for
otorhinolaryngologists. Rhinology 2012;50:1-12.
J ALLERGY CLIN IMMUNOL
VOLUME 135, NUMBER 4
WANG ET AL 9292. Van Bruaene N, Perez-Novo CA, Basinski TM, Van Zele T, Holtappels G,
De Ruyck N, et al. T-cell regulation in chronic paranasal sinus disease.
J Allergy Clin Immunol 2008;121:1435-41, e1-3.
3. Bachert C, Gevaert P, Holtappels G, Cuvelier C, van Cauwenberge P. Nasal
polyposis: from cytokines to growth. Am J Rhinol 2000;14:279-90.
4. Zhang N, Van Zele T, Perez-Novo C, Van Bruaene N, Holtappels G, DeRuyck N,
et al. Different types of T-effector cells orchestrate mucosal inflammation in
chronic sinus disease. J Allergy Clin Immunol 2008;122:961-8.
5. Small CB, Stryszak P, Danzig M, Damiano A. Onset of symptomatic effect of
mometasone furoate nasal spray in the treatment of nasal polyposis. J Allergy
Clin Immunol 2008;121:928-32.
6. Hissaria P, Smith W, Wormald PJ, Taylor J, Vadas M, Gillis D, et al. Short course
of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized,
placebo-controlled trial with evaluation of outcome measures. J Allergy Clin
Immunol 2006;118:128-33.
7. Vaidyanathan S, Barnes M, Williamson P, Hopkinson P, Donnan PT, Lipworth B.
Treatment of chronic rhinosinusitis with nasal polyposis with oral steroids
followed by topical steroids: a randomized trial. Ann Intern Med 2011;154:
293-302.
8. Basu K, Nair A, Williamson PA, Mukhopadhyay S, Lipworth BJ. Airway and
systemic effects of soluble and suspension formulations of nebulized budesonide
in asthmatic children. Ann Allergy Asthma Immunol 2009;103:436-41.
9. Hvizdos KM, Jarvis B. Budesonide inhalation suspension: a review of its use in
infants, children and adults with inflammatory respiratory disorders. Drugs 2000;
60:1141-78.
10. Fokkens W, Lund V, Mullol J. European position paper on rhinosinusitis and nasal
polyps 2007. Rhinol Suppl 2007;20:1-136.
11. Cao PP, Li HB, Wang BF, Wang SB, You XJ, Cui YH, et al. Distinct
immunopathologic characteristics of various types of chronic rhinosinusitis in adult
Chinese. J Allergy Clin Immunol 2009;124:478-84, e1-2.
12. Keith P, Nieminen J, Hollingworth K, Dolovich J. Efficacy and tolerability of
fluticasone propionate nasal drops 400 microgram once daily compared with
placebo for the treatment of bilateral polyposis in adults. Clin Exp Allergy
2000;30:1460-8.
13. Steinke JW, Payne SC, Tessier ME, Borish LO, Han JK, Borish LC. Pilot study of
budesonide inhalant suspension irrigations for chronic eosinophilic sinusitis.
J Allergy Clin Immunol 2009;124:1352-4.e7.
14. Sachanandani NS, Piccirillo JF, Kramper MA, Thawley SE, Vlahiotis A. The effect
of nasally administered budesonide respules on adrenal cortex function in
patients with chronic rhinosinusitis. Arch Otolaryngol Head Neck Surg 2009;
135:303-7.
15. Bhalla RK, Payton K, Wright ED. Safety of budesonide in saline sinonasal
irrigations in the management of chronic rhinosinusitis with polyposis: lack of
significant adrenal suppression. J Otolaryngol Head Neck Surg 2008;37:821-5.16. Welch KC, Thaler ER, Doghramji LL, Palmer JN, Chiu AG. The effects of
serum and urinary cortisol levels of topical intranasal irrigations with budesonide
added to saline in patients with recurrent polyposis after endoscopic sinus surgery.
Am J Rhinol Allergy 2010;24:26-8.
17. Hamilos DL. Chronic rhinosinusitis: epidemiology and medical management.
J Allergy Clin Immunol 2011;128:693-709.
18. Jankowski R, Schrewelius C, Bonfils P, Saban Y, Gilain L, Prades JM, et al.
Efficacy and tolerability of budesonide aqueous nasal spray treatment in patients
with nasal polyps. Arch Otolaryngol Head Neck Surg 2001;127:447-52.
19. Van Zele T, Gevaert P, Holtappels G, Beule A, Wormald PJ, Mayr S, et al. Oral
steroids and doxycycline: two different approaches to treat nasal polyps.
J Allergy Clin Immunol 2010;125:1069-76.e4.
20. Wen W, Liu W, Zhang L, Bai J, Fan Y, Xia W, et al. Increased neutrophilia in nasal
polyps reduces the response to oral corticosteroid therapy. J Allergy Clin Immunol
2012;129:1522-8.e5.
21. Li HB, Cai KM, Liu Z, Xia JH, Zhang Y, Xu R, et al. Foxp31 T regulatory cells
(Tregs) are increased in nasal polyps (NP) after treatment with intranasal steroid.
Clin Immunol 2008;129:394-400.
22. Li X, Meng J, Qiao X, Liu Y, Liu F, Zhang N, et al. Expression of TGF, matrix
metalloproteinases, and tissue inhibitors in Chinese chronic rhinosinusitis.
J Allergy Clin Immunol 2010;125:1061-8.
23. Mastruzzo C, Greco LR, Nakano K, Nakano A, Palermo F, Pistorio MP, et al.
Impact of intranasal budesonide on immune inflammatory responses and epithelial
remodeling in chronic upper airway inflammation. J Allergy Clin Immunol 2003;
112:37-44.
24. Molet SM, Hamid QA, Hamilos DL. IL-11 and IL-17 expression in nasal polyps:
relationship to collagen deposition and suppression by intranasal fluticasone
propionate. Laryngoscope 2003;113:1803-12.
25. Lee YM, Kim SS, Kim HA, Suh YJ, Lee SK, Nahm DH, et al. Eosinophil
inflammation of nasal polyp tissue: relationships with matrix metalloproteinases,
tissue inhibitor of metalloproteinase-1, and transforming growth factor-beta1.
J Korean Med Sci 2003;18:97-102.
26. Yigit O, Acioglu E, Gelisgen R, Server EA, Azizli E, Uzun H. The effect of
corticosteroid on metalloproteinase levels of nasal polyposis. Laryngoscope
2011;121:667-73.
27. Hoshino M, Takahashi M, Takai Y, Sim J. Inhaled corticosteroids decrease
subepithelial collagen deposition by modulation of the balance between matrix
metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in
asthma. J Allergy Clin Immunol 1999;104:356-63.
28. Namba M, Asano K, Kanai K, Kyo Y, Watanabe S, Hisamitsu T, et al. Suppression
of matrix metalloproteinase production from nasal fibroblasts by fluticasone
propionate in vitro. Acta Otolaryngol 2004;124:964-9.
29. Bruni FM, De Luca G, Venturoli V, Boner AL. Intranasal corticosteroids and
adrenal suppression. Neuroimmunomodulation 2009;16:353-62.
METHODS
Patients and study design
Sixty patients aged 19 to 76 years with eosinophilic NPs were recruited
into this prospective, randomized, double-blind, placebo-controlled
study (registration details are available at http://clinicaltrial.gov/show/
NCT02024659) from the Otolaryngology Clinic at Beijing TongRenHospital,
Beijing, China, from September 2010 to December 2011. All participants
were outpatients at the otolaryngology clinic and received diagnoses of
CRSwNP or symptoms of rhinosinusitis (eg, nasal obstruction, nasal
discharge, loss of smell, and headache/facial pain) for at least 12 weeksE1
from ear, nose, and throat specialists, which were confirmed by using
computed tomographic scanning for abnormalities in all sinuses. The presence
of bilateral NPs was also confirmed by using nasal endoscopy.
Patients who had undergone surgical treatment for NPs were not included
in the study, as were patients who had taken any steroids or antibiotics for at
least 4 weeks before sample collection. Patients with cystic fibrosis, any
serious or unstable concurrent disease, or psychological disorder and pregnant
women were also excluded from the study.
At the screening visit, participants were preselected for eosinophilic NPs
based on at least 1 of the following parameters: skin prick test response
positivity, increased eosinophil counts in peripheral blood, allergic rhinitis,
asthma, or aspirin intolerance. The diagnosis of CRSwNP was based on the
standard criteria issued in the European Position Paper on Rhinosinusitis and
Nasal Polyps guidelines.E1 Polyp biopsy was undertaken 1 week before
treatment. Referring to the method of Cao et al,E2 CRSwNP was defined as
eosinophilic when the number of eosinophils exceeded 10% of total
infiltrating inflammatory cells in the polyp tissue, as evaluated by using
H&E staining.
Eligible patients with eosinophilic NPs were randomly assigned 1:1 to
receive 1 mg/2 mL budesonide transnasal nebulization twice daily or
placebo transnasal nebulization (saline solution) for 14 days, according to a
computer-generated random allocation sequence using block randomization
with a block size of 4. An independent, off-site clinical trials pharmacist
masked the containers of budesonide inhalation suspension (Pulmicort
Respules, AstraZeneca) and placebo. The medications were distributed in
sequentially numbered sealed opaque envelopes at the research unit by a
laboratory technician and administered to the patients by a nurse, both of
whom were not involved with the study protocol, in a double-blind manner
with neither the patient nor any investigator connected with the study knowing
the identity of the medication. A Pari Sinus Nebulizer and Pari Master
Compressor (PARI GmbH) was used. Nebulization of the medication was
generally well tolerated and completed over a period of 5 to 10 minutes for
each dose. Nasal symptoms (including nasal obstruction, nasal discharge, loss
of smell, and headache/facial pain) were assessed before initiation (1 week
after biopsy) and at the end of the 14-day treatment period by using visual
analog scales. TNSSs were calculated as the sum of 4 individual symptoms at
the same time. Similarly, the size of NPs was measured by means of
endoscopic examination. Biopsy specimens of NPs were obtained again at
the end of the 14-day treatment period. In view of the relatively small sizes of
individual samples, all samples were evaluated by using H&E staining, and
then samples from patients in each treatment group were randomly divided
into approximately 3 equal groups. The 3 groups of samples were then
assessed for inflammatory cytokines, remodeling parameters, or T-cell
subsets. All patients were also assessed for pretreatment and posttreatment
morning serum cortisol levels to evaluate adrenal function, and adverse events
were reported to the investigator, who assessed the relationship of the event to
the study treatment.
Clinical evaluation
As the primary outcome, the physician’s assessment of reduction in NP size
was used. The investigator assessed the size of bilateral polyps by using
rhinoscopic examination at baseline and the end of the study with the Kennedy
score. Polyp size was scored as 0 (no polyps), 1 (polyps in the middle meatus
not reaching below the inferior border of the middle turbinate), 2 (polyps
reaching below the inferior border of the middle turbinate but not below the
inferior border of the inferior turbinate), or 3 (large polyps reaching below the
inferior turbinate). Bilateral polyp gradewas obtained as the sum of individual
grades for the left and right nasal cavities, with a possible total score of 6.
The patient’s assessment of symptom improvements was used as the
coprimary end point. Four major symptoms, including nasal obstruction,
discharge, loss of smell, and headache/facial pain, were assessed by the patient
using an ordinal scale visual analog score of 0 to 10, where 0 indicated the
absence of any symptoms and 10 signified the presence of the most
severe nasal obstruction, nasal discharge, alteration in sense of smell, and
headache/facial pain. An overall assessment of symptom severity was shown
as the TNSS, which was the sum of 4 individual symptoms.
Histologic examination
Paraffin sections were stained with H&E and observed by means of
bright-field light microscopy at 3400 magnification. Numbers of infiltrating
eosinophils were counted and reported as the mean of counts for at least 10
randomized fields by 2 independent observers who were blind to the clinical
diagnosis and characteristics of the patient. In case of disagreement
(ie, difference >10% between the 2 counts), the specimen was observed
further by using a multihead microscope, and consensus was reached on the
count accordingly.
Immunoassay
Samples to be assessed by means of immunoassay were weighed, and a
total of 1.0 mL of PBS supplemented with 0.05% Tween 20 (Sigma-Aldrich,
St Louis, Mo) and 1% protease inhibitor cocktail (Sigma-Aldrich) was added
for every 100 mg of tissue. All samples were homogenized with a standard
bench-top homogenizer (Polytron PT 2100, Kinematica, Switzerland) at
1000 rpm for 5 minutes, and the homogenates were centrifuged at 1500g for
10 minutes at 48C. The supernatants were collected from each sample and
stored at2808C until further analysis for a variety of inflammatory cytokines,
MMPs, TIMPs, and albumin.
Expression of MMPs (MMP-2, MMP-7, MMP-8, and MMP-9) and TIMP
isoforms (TIMP-1, TIMP-2, TIMP-3, and TIMP-4) was assessed by using
Fluorokine MAP Multiplex Kits (R&D Systems, Minneapolis, Minn) and
analyzed on a Luminex 100 analyzer (Luminex 100 System; Luminex, Austin,
Tex). IL-5, IFN-g, IL-17, IL-10, and eotaxin concentrations were measured by
using the BD Cytometric Bead Array Human Enhanced Sensitivity Flex Set
System (BD Biosciences), which uses particles with discrete fluorescence
intensities to obtain the concentration of analytes. Albumin and TGF-b levels
in tissue homogenates were determined by using commercially available
ELISA kits (R&D Systems).
Picrosirius red staining for collagen
The collagen content in the extracellular matrix was assessed by using
picrosirius red staining, as reported by Li et al.E3 Briefly, paraffin sectionswere
deparaffinized, hydrated, and stained with picrosirius red for 60 minutes. The
stained sections werewashed in 2 changes of acidifiedwater and dehydrated in
3 changes of 100% ethanol before analysis by means of microscopy with an
Olympus microscope (CX-40) equipped with filters to provide circularly
polarized illumination. The tissue images were viewed under both
bright-field and polarized light conditions at3200magnification and recorded
with a digital camera (Olympus BX-41).
Collagen content was calculated in the digital images taken during
bright-field microscopy. The percentage of positively stained area was
determined from 10 randomly selected fields per sample to analyze total
collagen content, and collagen type 3 fibers present in the tissue were
determined by using polarized light microscopy.
Flow cytometric analysis
Fresh polyp tissues were washed and cut into small fragments before
teasing apart to allow dispersion of the nasal cells into RPMI 1640 media
(Life Technologies, Rockville, Md). The dispersed samples were passed
through a 40-mm pore size mesh to obtain a single-cell suspension, and after
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rinsing with fresh RPMI 1640 medium, cells were adjusted to a concentration
of 2 3 106 cells/mL.
T-cell subsets in polyp tissueswere phenotyped bymeans of flow cytometry
(FACSAria Flow Cytometer, BD Biosciences), according to the manufac-
turer’s instructions. We gated on lymphocytes first based on forward scatter
and side scatter and then gated on CD41 cells with anti-CD4–allophycocyanin
H7 (12 mg/mL), which could be stained only on live cells, excluding dead
cells/doublets. Each antibody was matched with a respective isotype IgG1
as a control, and the gating threshold was set accordingly. Cells were labeled
with specific mAbs in different combinations as follows: anti-CD25–PerCP
CY7 (12 mg/mL), anti–IL-4–Alexa Flour 488 (0.125 mg/5 mL), anti–IL-10–
phycoerythrin (0.03 mg/20 mL), anti–IL-17A Alexa Flour 647 (0.25 mg/20
mL), anti–IFN-g–PerCP-CY5.5 (0.06 mg/5 mL), and Foxp3–Horizon V450
(50 mg/mL; all from BD PharMingen, San Jose, Calif). T-cell subsets were
selected for detailed phenotypic analysis as follows: (1) TH1 cells were
REFERENCES
E1. Fokkens W, Lund V, Mullol J. European position paper on rhinosinusitis and
nasal polyps 2007. Rhinol Suppl 2007;20:1-136.
E2. Cao PP, Li HB, Wang BF, Wang SB, You XJ, Cui YH, et al. Distinct
immunopathologic characteristics of various types of chronic rhinosinusitis in
adult Chinese. J Allergy Clin Immunol 2009;124:478-84, e1-2.
E3. Li X, Meng J, Qiao X, Liu Y, Liu F, Zhang N, et al. Expression of TGF, matrix
metalloproteinases, and tissue inhibitors in Chinese chronic rhinosinusitis.
J Allergy Clin Immunol 2010;125:1061-8.
IFN-g1IL-42CD41 T cells; (2) TH2 cells were IFN-g
2IL-41CD41 T cells;
(3) TH17 cells were IL-17A
1CD41 T cells; (4) TR1 cells were
IL-101IL-42CD41 T cells; and (5) nTreg cells were CD41CD251Foxp31
T cells. Representative gating figures are shown in Fig E1.
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FIG E1. Representative gating figures in flow cytometric analysis of TH1, TH2, TH17, TR1, and nTreg cells in
tissue homogenates.A, CD41 T cells (scatter dots in the semicircle)were gated. B, Isotype control of TH1 and
TH2 cells (left lower quadrant). C, TH1 cells (IFN-g
1IL-42CD41 T cells, right lower quadrant) and TH2 cells
(IL-41IFN-g2CD41 T cells, left upper quadrant) were gated in CD41 T cells. D, Isotype control of TH17 cells
(left upper quadrant). E, TH17 cells (IL-17
1CD41 T cells, right upper quadrant) were gated in CD41 T cells.
F, Isotype control of TR1 cells (left lower quadrant).G, TR1 cells (IL-10
1IL-42CD41 T cells, left upper quadrant)
were gated in CD41 T cells. H, Isotype control of CD251Foxp31 cells (left lower quadrant). I, nTreg cells
(CD41CD251Foxp31 T cells, right upper quadrant) were gated in CD41 T cells. Values in dot plots indicate
percentages of different cell subsets in total CD41 T cells.
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FIG E2. Eosinophil infiltration in polyp tissues (3400 magnification) decreased from before (A) to after
(B) treatment in the budesonide transnasal nebulization group.
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FIG E3. Correlation between the change in TGF-b levels and the
change in nTreg cell numbers from baseline in the budesonide transnasal
nebulization–treated group.
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TABLE E1. Clinical characteristics of patients with NPs at
baseline
Characteristic
Patients with NPs
Budesonide group Placebo group
No. 30 30
Age (y), mean (range) 48.23 (29-68) 44.03 (19-76)
Sex (male/female) 12/18 17/13
Duration (y), mean (range) 10.67 (4-24) 8.57 (2-20)
Asthma in history 11 9
Aspirin intolerance 7 5
Polyp size score, mean (SD) 4.85 (0.69) 4.72 (0.67)
TNSS, mean (SD) 28.52 (2.32) 27.36 (2.15)
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